Category: Advocacy
-

Job offer for the MENA regional platform manager on Global Fund and Civil Society
JOB DESCRIPTION: REGIONAL GLOBAL FUND PLATFORM MANAGER ABOUT ITPC-MENA: International Treatment Preparedness Coalition (ITPC) Middle East & North Africa (MENA) is a regional non governmental organization operating in the Middle East and North Africa region regrouping a network of community activists united by our vision of a longer, healthier, more productive life for people living…
-

IAS 2017: Closing ceremony exposes Gilead Sciences
Conference funders, Gilead Sciences, named and shamed for its “insatiable greed” Yesterday, the 9th International AIDS Conference on HIV Science in Paris (IAS 2017), drew to a close, in style. The community address delivered by Othoman Mellouk, during the closing ceremony, exposed one of the key conference sponsors, Gilead. Mellouk, who is the Intellectual Property…
-

A new victory for ITPC-MENA : Bristol-Myers Squibb extends its voluntary license on Atazanavir to Egypt
The 9th International AIDS Society Conference on HIV / AIDS 2017 : Bristol-Myers Squibb extends its voluntary license on Atazanavir to Egypt, a victory for ITPC-MENA Today, at the World Conference on AIDS, which is currently taking place in Paris from the 23rd to 26th July 2017, Bristol-Myers Squibb (BMS) and the Medicines Patent Pool…
-

BLOG: We want dolutegravir for all, and we want it now
Source: makemedicinesaffordable Author: Othoman Mellouk, Intellectual Property and Access to Medicines Lead at the International Treatment Preparedness Coalition (ITPC). Article first published on the Huffington Post here. We’re calling for a compulsory license on a ‘new’ HIV drug to be enacted simultaneously in an initial six countries, in order to get essential treatment to all…
-

HIV Activists Denounce ViiV for Denying 3.5 million People Access to Optimal Treatment
Source : ITPC GLOBAL Today, Monday, 24 July 2017, during the 9th International AIDS Conference on HIV Science in Paris (IAS 2017), HIV treatment activists from around the world collectively blocked access to ViiV Healthcare’s promotional booth and stormed its presentation to physicians. The action, which included taping off ViiV’s booth, to deny access to…
-

ITPC MENA IN THE REGIONAL CONSULTATION ON ACCELERATING ACCESS TO THE CONTIUUM OF HIV CARE: FOCUS ON HIV TESTING
Beirut, Lebanon, 12–14 July 2017 By the end of 2015, the estimated number of people living with HIV in the Region had reached 330 000. With a continuously growing epidemic coupled with low coverage of ART, standing at 14% of people living with HIV, the number of deaths among people living with HIV was 15…
-

New WHO Guidance Report- Treatment Failure and Drug Resistance
WHO urges action against HIV drug resistance threat 20 JULY 2017 | GENEVA – WHO alerts countries to the increasing trend of resistance to HIV drugs detailed in a report based on national surveys conducted in several countries. The Organization warns that this growing threat could undermine global progress in treating and preventing HIV infection if…
-

US Supreme Court Adopts International Exhaustion For Patents: Paving the way for parallel imports to exert downward pressure on domestic pharmaceutical (and other) prices
Source : By Frederick M The Supreme Court of the United States on May 30, 2017 adopted a rule of international exhaustion of patent rights for the United States in Impression Products v. Lexmark International, No. 15-1189. The near-unanimous decision authored by Chief Justice Roberts is unambiguous and unequivocal.[1] The Court paid short shrift to…
-

Access to medicines amendment of the WTO TRIPS Agreement– hype or hope?
By: Ellen ‘t Hoen, Global Health Unit Department of Health Sciences, UMCG Groningen, e.f.m.t.hoen@umcg.nl On 30 January the World Trade Organization (WTO) announced the first ever amendment to the TRIPS Agreement under the headline WTO members welcome entry into force of amendment to ease access to medicines. WTO members were celebrating and some media reported the…
-

The HepC Pill Bill
Source : hepCoalition The HepC Pill Bill-An insight into the availability, pricing and accessibility of HCV treatment Introduction to Direct Acting Antivirals Hepatitis C treatment has remarkably evolved over the years. The previously known standard HCV regimen consisted of a course of pegylated interferon injections and ribavirin tablets, which all in all were expensive, toxic,…